Tyrosine kinase inhibitors

From Libre Pathology
Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Tyrosine kinase inhibitors, abbreviated TKIs, are a group of drugs that inhibit the action of tyrosine kinases.

The category includes many cancer drugs - including:

  • Imatinib (Gleevec).
  • Gefitinib (Iressa).
  • Erlotinib (Tarceva).

Others - used in RCC:[1]

  • Sunitinib (Sutent).
  • Sorafenib (Nexavar).
  • Pazopanib (Votrient).

Use

See also

References

  1. URL: http://dtb.bmj.com/content/49/11/129.abstract. Accessed on: 3 October 2014
  2. Song, Z.; Lin, B.; Shao, L.; Zhang, Y. (Sep 2013). "Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.". J Chin Med Assoc 76 (9): 481-5. doi:10.1016/j.jcma.2013.05.007. PMID 23769878.
  3. Elaidi, R.; Harbaoui, A.; Beuselinck, B.; Eymard, JC.; Bamias, A.; De Guillebon, E.; Porta, C.; Vano, Y. et al. (Feb 2015). "Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma.". Ann Oncol 26 (2): 378-85. doi:10.1093/annonc/mdu552. PMID 25467013.
  4. Verma, J.; Jonasch, E.; Allen, P.; Tannir, N.; Mahajan, A. (Nov 2011). "Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.". Cancer 117 (21): 4958-65. doi:10.1002/cncr.26138. PMID 21484781.